N/A
Completed N=60
Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI
Source: ClinicalTrials.gov NCT02395991 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
May 2021
Primary outcomePrimary: Number of Participants With Transient Dyspnea. — 23 Participants
Summary
The purpose of this study is to observe transient dyspnea pattern after Gd-EOB-DTPA administration by obtaining continuous dynamic T1 weighted image data.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Transient Dyspnea. |
23 | — |
| SECONDARY Duration of Transient Dyspnea in Participants With Transient Dyspnea. |
21.5 | — |
Eligibility Criteria
Inclusion Criteria
- Patients who are referred to MR unit for hepatocyte-specific contrast enhanced liver MRI using gadoxetic acid, to characterize focal liver lesion or to investigate diffuse liver disease
- OR, Liver living donor candidates
- AND subjects who sign the informed consent.
Exclusion Criteria
- Minors under 18 years old
- All contraindication to MRI
- Hypersensitivity to Gd
- Biliary obstruction
Data sourced from ClinicalTrials.gov (NCT02395991). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.